1 results match your criteria: "Vreije Universiteit Medical Center[Affiliation]"
Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients.
J Clin Oncol
April 2006
Department of Medical Oncology, Vreije Universiteit Medical Center, Amsterdam, The Netherlands.
Purpose: The efficacy of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) gefitinib was assessed in a phase II study in patients with advanced esophageal cancer. Several biologic features were investigated as potential markers of gefitinib activity.
Patients And Methods: Patients with advanced esophageal cancer, who had failed one line of prior chemotherapy, were administered gefitinib 500 mg/d.